- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Part A: Placebo, Nintedanib, GSK3915393
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Cypress, California • Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more